[EN] OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS<br/>[FR] DÉRIVÉS D'OXOAZÉTIDINE, PROCÉDÉ POUR LA PRÉPARATION DE CEUX-CI ET UTILISATION DE CEUX-CI DANS LA MÉDECINE HUMAINE ET DANS LES COSMÉTIQUES
申请人:GALDERMA RES & DEV
公开号:WO2010052253A1
公开(公告)日:2010-05-14
The present invention relates to novel compounds derived from oxoazetidine corresponding to general formula (I) to the compositions containing same, to the process for preparation thereof and to the use thereof in pharmaceutical or cosmetic compositions.
[EN] PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS<br/>[FR] DERIVES DE PHENYLPYRIDAZINE UTILISES EN TANT QUE LIGANDS POUR DES RECEPTEURS GABA
申请人:MERCK SHARP & DOHME
公开号:WO2004014865A1
公开(公告)日:2004-02-19
A class of 4-phenylpyridazine derivatives of Formula (I), being selective ligands for GABAA receptors, in particular having high affinity for the α2 and/or α3 and or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
Formula (I)的4-苯基吡啶并衍生物是GABAA受体的选择性配体,特别是对其α2和/或α3和/或α5亚基具有高亲和力,因此在治疗和/或预防中枢神经系统的不良状况,包括焦虑、抽搐和认知障碍方面具有益处。
[EN] AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE<br/>[FR] ANALOGUES DE L'AFMT ET LEUR UTILISATION DANS DES MÉTHODES DE TRAITEMENT DE LA MALADIE DE PARKINSON
申请人:HARVARD COLLEGE
公开号:WO2021216781A1
公开(公告)日:2021-10-28
The present disclosure provides compounds of formula (I), (II), and (la): Methods of preparing these molecules and their use for treatment of Parkinson's Disease are described.
The invention provides methods and compositions for in vivo incorporation of unnatural amino acids. Also provided are compositions including proteins with unnatural amino acids.
本发明提供了在体内合成非天然氨基酸的方法和组合物。同时还提供了包括非天然氨基酸蛋白质的组合物。
IN Vivo Incorporation of Unnatural Amino Acids
申请人:SCHULTZ PETER G.
公开号:US20120202243A1
公开(公告)日:2012-08-09
The invention provides methods and compositions for in vivo incorporation of unnatural amino acids. Also provided are compositions including proteins with unnatural amino acids.